Sterifre Medical Inc.

Weill Cornell Medicine’s Laboratory of Bioregenerative Medicine Surgery (LBMS) will work with Sterifre Medical Inc. toward the commercialization of a new wound therapy device that delivers a patented therapeutic effluent to a wound site via gas-phase resulting in rapid, pain-free wound disinfection for the treatment of acute & chronic wounds. This treatment has practical and biological advantages over liquid and topical treatments and has the flexibility to account for different therapeutic needs. The FuzeHub Manufacturing Innovation Grant will help the team acquire key data necessary to securing FDA approval for a first-in-human study in 2018.